InnoCare Pharma Limited (InnoCare) has completed the first grant under its 2026 RMB Share Incentive Scheme, issuing 8.00 million restricted shares to 100 eligible employees after market close on 16 June 2026. The allotment represents approximately 0.45% of the company’s total issued share capital.

Key terms of the grant • Grant date: 16 June 2026 • Number of shares: 8.00 million RMB-denominated ordinary shares • Purchase price: RMB 14.47 per share • Market reference prices at grant: HK$ 10.71 per Hong Kong-listed share; RMB 22.56 (≈ HK$ 26.15) per STAR Market-listed share

Vesting and performance conditions • Vesting schedule: 25 % of the award vests on the first trading day after 12 months from the grant date, with a further 25 % vesting on each of the next three anniversaries, subject to performance reviews. • Company-level targets: Vesting proportion is linked to cumulative operating revenue or number of clinical trials achieved from 2026 through the relevant assessment year. • Individual-level targets: Vesting is contingent on meeting one of three prescribed performance grades. • Clawback: Unvested shares will be cancelled if specific adverse events occur at either company or employee level, including an adverse audit opinion or regulatory sanctions against a participant.

Participant profile and compliance • None of the 100 grantees is a director, chief executive, substantial shareholder, related-entity participant or service provider whose awards exceed the thresholds set out in Hong Kong Listing Rule 17.03D. • The company and its subsidiaries will not offer any financial assistance for share purchases. • The restricted shares carry no voting or dividend rights prior to vesting and registration.

Remaining scheme capacity Following this initial allocation, 2.00 million shares remain available for issuance under the 2026 RMB Share Incentive Scheme.

Rationale The board states the grant is intended to strengthen long-term incentives, attract and retain talent, align employee interests with those of shareholders and support the company’s sustained development.